, through its subsidiaries, provides enabling technologies and products for the separation, purification, and handling of nucleic acids and proteins.
It offers a portfolio of consumable products for nucleic acid and protein separation, purification and handling, and nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products, and related services.
Its consumable products applications include plasmid deoxyribonucleic (DNA) acid purification; ribonucleic acid (RNA) stabilization and purification; genomic and viral nucleic acid purification; nucleic acid transfection; PCR amplification; reverse transcription; DNA cleanup after PCR and sequencing; DNA cloning and protein purification.
Its BioRobot systems offer automation of nucleic acid preparation in low, medium, or high throughput scale, as well as reaction set-up and other laboratory tasks.
The company also offers custom services, small interfering RNA synthesis, whole genome amplification services, DNA sequencing, and noncGMP and cGMP DNA production on a contract basis.
The company sells its products to academic research markets, and pharmaceutical and biotechnology companies, as well as developing commercial markets, including applied testing markets, clinical research, nucleic acid-based molecular diagnostics, and genetic vaccination, and gene therapy.
It operates in the United States, Germany, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden, and the Netherlands.
The company was incorporated in 1996 as QIAGEN N.V.
It was co-founded in Detlev H.
Riesner and Metin Colpan.
QIAGEN is headquartered in Venlo, The Netherlands.
